Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 2
1992 2
1993 2
1994 5
1995 4
1996 9
1997 10
1998 16
1999 14
2000 13
2001 13
2002 11
2003 15
2004 31
2005 37
2006 40
2007 44
2008 57
2009 63
2010 41
2011 47
2012 42
2013 52
2014 39
2015 52
2016 40
2017 32
2018 34
2019 28
2020 24
2021 21
2022 10
2023 21
2024 26
2025 21
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

796 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Venlafaxine's therapeutic reference range in the treatment of depression revised: a systematic review and meta-analysis.
Lense XM, Hiemke C, Funk CSM, Havemann-Reinecke U, Hefner G, Menke A, Mössner R, Riemer TG, Scherf-Clavel M, Schoretsanitis G, Gründer G, Hart XM. Lense XM, et al. Psychopharmacology (Berl). 2024 Feb;241(2):275-289. doi: 10.1007/s00213-023-06484-7. Epub 2023 Oct 19. Psychopharmacology (Berl). 2024. PMID: 37857898 Free PMC article.
INTRODUCTION: The selective serotonin and norepinephrine reuptake inhibitor venlafaxine is among the most prescribed antidepressant drugs worldwide and, according to guidelines, its dose titration should be guided by drug-level monitoring of its active moiety (AM) which co …
INTRODUCTION: The selective serotonin and norepinephrine reuptake inhibitor venlafaxine is among the most prescribed antidepressant d …
The risks of adverse events with venlafaxine for adults with major depressive disorder: a systematic review of randomised clinical trials with meta-analysis and Trial Sequential Analysis.
Kamp CB, Petersen JJ, Faltermeier P, Juul S, Siddiqui F, Moncrieff J, Horowitz MA, Hengartner MP, Kirsch I, Gluud C, Jakobsen JC. Kamp CB, et al. Epidemiol Psychiatr Sci. 2024 Oct 23;33:e51. doi: 10.1017/S2045796024000520. Epidemiol Psychiatr Sci. 2024. PMID: 39440379 Free PMC article.
AIMS: Venlafaxine is used to treat depression worldwide. Previous reviews have demonstrated that venlafaxine lowers scores on depression rating scales, producing statistically significant results but the relevance to patients remains uncertain. ...The long-term effe …
AIMS: Venlafaxine is used to treat depression worldwide. Previous reviews have demonstrated that venlafaxine lowers scores on …
Venlafaxine for neuropathic pain in adults.
Gallagher HC, Gallagher RM, Butler M, Buggy DJ, Henman MC. Gallagher HC, et al. Cochrane Database Syst Rev. 2015 Aug 23;2015(8):CD011091. doi: 10.1002/14651858.CD011091.pub2. Cochrane Database Syst Rev. 2015. PMID: 26298465 Free PMC article.
Four of the six studies reported some positive benefit for venlafaxine. In the largest study by Rowbotham, 2004, 56% of participants receiving venlafaxine 150 to 225 mg achieved at least a 50% reduction in pain intensity versus 34% of participants in the placebo gro …
Four of the six studies reported some positive benefit for venlafaxine. In the largest study by Rowbotham, 2004, 56% of participants …
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Kishi T, Ikuta T, Sakuma K, Okuya M, Hatano M, Matsuda Y, Iwata N. Kishi T, et al. Mol Psychiatry. 2023 Jan;28(1):402-409. doi: 10.1038/s41380-022-01824-z. Epub 2022 Oct 17. Mol Psychiatry. 2023. PMID: 36253442 Free PMC article.
Compared to placebo, venlafaxine was associated with a lower incidence of dizziness, while desvenlafaxine, sertraline, and vortioxetine were associated with a higher incidence of nausea/vomiting. In conclusion, desvenlafaxine, paroxetine, venlafaxine, and vortioxeti …
Compared to placebo, venlafaxine was associated with a lower incidence of dizziness, while desvenlafaxine, sertraline, and vortioxeti …
Effect of venlafaxine on anhedonia and amotivation in patients with major depressive disorder.
McIntyre RS, Agid O, Biesheuvel E, Purushottamahanti P. McIntyre RS, et al. CNS Spectr. 2024 Jun;29(3):206-214. doi: 10.1017/S1092852924000245. Epub 2024 Apr 30. CNS Spectr. 2024. PMID: 38685594 Clinical Trial.
This post hoc pooled analysis evaluated the effect of venlafaxine XR, an SNRI, on these symptoms in patients with major depressive disorder (MDD). METHODS: Data was pooled from five short-term randomized, placebo-controlled studies of venlafaxine XR for the treatmen …
This post hoc pooled analysis evaluated the effect of venlafaxine XR, an SNRI, on these symptoms in patients with major depressive di …
Venlafaxine XR in the treatment of anxiety.
Hackett D. Hackett D. Acta Psychiatr Scand Suppl. 2000;(406):30-5. Acta Psychiatr Scand Suppl. 2000. PMID: 11131468
OBJECTIVE: To present the results of numerous studies that assessed the efficacy, safety and tolerability of venlafaxine extended release (XR) in treating anxiety disorders, particularly generalized anxiety disorder (GAD). ...RESULTS: In four placebo-controlled trials, …
OBJECTIVE: To present the results of numerous studies that assessed the efficacy, safety and tolerability of venlafaxine extended rel …
Clinical evaluation of venlafaxine.
Ballenger JC. Ballenger JC. J Clin Psychopharmacol. 1996 Jun;16(3 Suppl 2):29S-35S; discussion 35S-36S. doi: 10.1097/00004714-199606002-00007. J Clin Psychopharmacol. 1996. PMID: 8784646 Review.
Recent studies have shown venlafaxine to be an effective first-line agent for patients who have depression of varying severity. ...Demographics and baseline scores were similar among study patients in each trial. In both trials, venlafaxine was significantly more ef …
Recent studies have shown venlafaxine to be an effective first-line agent for patients who have depression of varying severity. ...De …
Differences in the placebo response in duloxetine and venlafaxine trials.
Breilmann J, Furukawa TA, Becker T, Koesters M. Breilmann J, et al. Acta Psychiatr Scand. 2018 Jun;137(6):472-480. doi: 10.1111/acps.12881. Epub 2018 Mar 30. Acta Psychiatr Scand. 2018. PMID: 29603140
METHOD: We conducted a comprehensive systematic review and meta-analysis of placebo-controlled, double-blind RCTs, which examined the efficacy of duloxetine and venlafaxine in the acute treatment of major depressive disorder. RESULTS: We included 71 studies (29 duloxetine …
METHOD: We conducted a comprehensive systematic review and meta-analysis of placebo-controlled, double-blind RCTs, which examined the effica …
Dose-response relationship with venlafaxine.
Kelsey JE. Kelsey JE. J Clin Psychopharmacol. 1996 Jun;16(3 Suppl 2):21S-26S; discussion 26S-28S. doi: 10.1097/00004714-199606002-00005. J Clin Psychopharmacol. 1996. PMID: 8784645 Review.
Considerations when selecting a first-line antidepressant agent include the potential for achieving greater response with increasing dosages, thereby allowing greater flexibility in dosing. The efficacy and dose-response of venlafaxine, a novel serotonin and norepinephrine …
Considerations when selecting a first-line antidepressant agent include the potential for achieving greater response with increasing dosages …
The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis.
Bauer M, Tharmanathan P, Volz HP, Moeller HJ, Freemantle N. Bauer M, et al. Eur Arch Psychiatry Clin Neurosci. 2009 Apr;259(3):172-85. doi: 10.1007/s00406-008-0849-0. Epub 2009 Jan 22. Eur Arch Psychiatry Clin Neurosci. 2009. PMID: 19165525
Compared to placebo the odds ratio for relapse prevention with venlafaxine was 0.37 (95% CI 0.27-0.51). CONCLUSION: This meta analysis provides evidence of the clinical efficacy of venlafaxine in achieving therapeutic response and remission in patients with major de …
Compared to placebo the odds ratio for relapse prevention with venlafaxine was 0.37 (95% CI 0.27-0.51). CONCLUSION: This meta analysi …
796 results